Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Novartis Unveils Promising Data for Potential First Targeted Sjögren's Treatment

Novartis Unveils Promising Data for Potential First Targeted Sjögren's Treatment

Novartis has presented late-breaking Phase III data for ianalumab, a dual-targeted antibody showing significant promise in reducing disease activity and patient burden in Sjögren's disease. The results, unveiled at the American College of Rheumatology Convergence congress, mark a potential breakthrough in the treatment of this common autoimmune condition.

NoahAI News10/30/2025
Genentech Announces Major Layoffs Amid Strategic Shifts and Clinical Successes

Genentech Announces Major Layoffs Amid Strategic Shifts and Clinical Successes

Genentech, a subsidiary of Roche, has announced its third round of layoffs this year, bringing the total number of employees let go in San Francisco to 348 in 2025. This latest round, affecting 118 staff members, comes on the heels of significant changes in the company's partnerships and research focus.

NoahAI News10/30/2025
BridgeBio's Double Success: Thyroid Drug Shines in Phase III, Shares Soar

BridgeBio's Double Success: Thyroid Drug Shines in Phase III, Shares Soar

BridgeBio Pharma, Inc. has reported impressive Phase III results for its thyroid drug encaleret, marking the company's second major success this week. The genetic disease biotech's shares have surged nearly 8% following the announcement, building on momentum from earlier positive results in limb-girdle muscular dystrophy.

NoahAI News10/30/2025
Regeneron's Eylea HD Faces Setbacks, But Company Remains Optimistic

Regeneron's Eylea HD Faces Setbacks, But Company Remains Optimistic

Regeneron Pharmaceuticals has encountered another obstacle in its quest to bring the high-dose (HD) version of its blockbuster drug Eylea to market. The U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the pre-filled syringe formulation of Eylea HD, citing manufacturing issues at a third-party facility. Despite this setback, the company is actively pursuing alternative manufacturing solutions and remains confident in the drug's future.

NoahAI News10/30/2025
Eli Lilly and Walmart Partner to Enhance Access to Weight Loss Drug Zepbound

Eli Lilly and Walmart Partner to Enhance Access to Weight Loss Drug Zepbound

Pharmaceutical giant Eli Lilly has announced a groundbreaking collaboration with retail behemoth Walmart, marking a significant expansion in the accessibility of its weight loss medication, Zepbound. This partnership, set to launch in mid-November, represents the first retail pickup option for Lilly's direct-to-consumer platform, LillyDirect, and promises to reshape how patients access and manage their obesity treatments.

NoahAI News10/30/2025
LGBTQ+ Mental Health Startup Allswell Secures $1.3M in Pre-Seed Funding to Address Care Gaps

LGBTQ+ Mental Health Startup Allswell Secures $1.3M in Pre-Seed Funding to Address Care Gaps

Allswell, a virtual mental health provider focused on serving LGBTQ+ patients, has raised $1.3 million in pre-seed funding to expand its services and address the significant mental health care gaps faced by the LGBTQ+ community. The round was led by Amboy Street Ventures, with participation from Seae Ventures' Unseen Capital, Techstars, and others.

NoahAI News10/30/2025
Aldeyra Therapeutics Reshapes Pipeline, Extends Cash Runway

Aldeyra Therapeutics Reshapes Pipeline, Extends Cash Runway

Aldeyra Therapeutics, a biotechnology company focused on developing novel therapies for immune-mediated diseases, has announced significant changes to its drug development pipeline. The company's strategic shift involves discontinuing one asset while advancing two others, a move that extends its financial resources and refocuses its research priorities.

NoahAI News10/30/2025
Big Pharma Embraces AI: J&J and Lilly Partner with Nvidia for Cutting-Edge Technology Integration

Big Pharma Embraces AI: J&J and Lilly Partner with Nvidia for Cutting-Edge Technology Integration

Eli Lilly and Johnson & Johnson have joined the ranks of pharmaceutical giants investing heavily in artificial intelligence (AI), announcing separate partnerships with tech leader Nvidia. These collaborations aim to revolutionize drug discovery, development processes, and medical device applications, signaling a new era in the pharmaceutical industry's approach to innovation.

NoahAI News10/30/2025
EmblemHealth Partners with Prime Therapeutics and Amazon for Innovative Pharmacy Benefit Solution

EmblemHealth Partners with Prime Therapeutics and Amazon for Innovative Pharmacy Benefit Solution

New York-based insurer EmblemHealth has announced a groundbreaking collaboration with Prime Therapeutics and Amazon to revolutionize the pharmacy benefit experience for its members. This strategic partnership aims to simplify the process, increase transparency, and provide more affordable options in response to rising pharmaceutical costs.

NoahAI News10/30/2025
Thermo Fisher Scientific to Acquire Clario Holdings in $8.9 Billion Deal

Thermo Fisher Scientific to Acquire Clario Holdings in $8.9 Billion Deal

Thermo Fisher Scientific, a leading player in the pharmaceutical and biotechnology industry, has announced a significant acquisition that is set to reshape the landscape of clinical trial data management. The company will acquire Clario Holdings, a prominent clinical trial data firm, for $8.9 billion in cash, with additional performance-based payments potentially reaching $525 million.

NoahAI News10/30/2025
Lilly Expands Access to Obesity Drug Zepbound Through Walmart Partnership

Lilly Expands Access to Obesity Drug Zepbound Through Walmart Partnership

Eli Lilly has announced a strategic partnership with Walmart to broaden access to its obesity medication Zepbound, marking a significant development in the pharmaceutical giant's direct-to-consumer initiatives. The collaboration, set to launch in mid-November, will allow patients to pick up Zepbound orders placed through Lilly's online service at Walmart pharmacies, offering a discounted cash-pay option that bypasses traditional insurance channels.

NoahAI News10/30/2025
Novartis Reports Promising Phase 3 Results for Sjögren's Syndrome Drug Ianalumab

Novartis Reports Promising Phase 3 Results for Sjögren's Syndrome Drug Ianalumab

Novartis has unveiled encouraging results from two phase 3 clinical trials evaluating ianalumab, its investigational monoclonal antibody for the treatment of Sjögren's syndrome. The studies, known as Neptunus-1 and Neptunus-2, mark a significant milestone in the development of potential therapies for this autoimmune disease, which currently lacks approved systemic treatments.

NoahAI News10/30/2025
«1...111213...67»